{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:31Z","timestamp":1792789051717,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca Farmac\u00e9utica Spain S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: The SRealCLL study described the occurrence of adverse events (AEs) and healthcare resource utilization in patients with chronic lymphocytic leukaemia (CLL) using artificial intelligence in a real-world scenario in Spain. Methods: We collected real-world data on patients with CLL from seven Spanish hospitals between January 2016 and December 2018, focusing on their AE and healthcare service utilization. Data extraction from electronic health records of 385,904 patients was performed using the EHRead\u00ae technology, which is based on natural language processing and machine learning. Results: Among the 534 CLL patients finally included, 270 (50.6%) were categorized as watch and wait (W&amp;W), 230 (43.1%) as first-line treatment (1L), and 58 (10.9%) as relapse\/refractory with second-line treatment (2L). The median study follow-up periods were 14.4, 8.4, and 6 months for W&amp;W, 1L, and 2L, respectively. The most common antineoplastic treatments were ibrutinib (64.8%) and bendamustine + rituximab (12.6%) in 1L, and ibrutinib (62.1%) and venetoclax (15.5%) in 2L. Among the most frequent AEs, anaemia and thrombocytopenia presented higher rates in the treated groups (1L and 2L) compared with W&amp;W (2.01 and 2.32 vs. 0.93; p \u2264 0.05 and 1.29 and 1.62 vs. 0.42; p \u2264 0.05). Moreover, several AEs, such as major bleeding, digestive symptoms, general symptoms, or Richter syndrome, were more frequent in 1L than W&amp;W (all p \u2264 0.05). No differences were shown between groups in the rates of outpatient visits. However, rates of outpatient visits due to AE were higher in 1L than in W&amp;W (1.07 vs. 0.65, p \u2264 0.05). The rates of patients being hospitalized were higher in the treated groups compared to W&amp;W (1.68 and 1.9 vs. 0.88; p \u2264 0.05), and those due to AE were higher in 1L than W&amp;W (1.23 vs. 0.60; p \u2264 0.05). Conclusions: Patients with CLL in 1L or 2L treatments often require healthcare resources due to AEs, particularly cytopenias. The methodology used in this study likely enabled us to identify higher rates of AEs that may be underreported using other real-world approaches. Addressing AEs with effective agents that maximize patient safety and optimize healthcare resource use is crucial in this typically older and comorbid population.<\/jats:p>","DOI":"10.3390\/cancers16234004","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:02:22Z","timestamp":1732856542000},"page":"4004","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-7422","authenticated-orcid":false,"given":"Pau","family":"Abrisqueta-Costa","sequence":"first","affiliation":[{"name":"Haematology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-5982","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Garc\u00eda-Marco","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-077X","authenticated-orcid":false,"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Son Espases, IdISBa, 07120 Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-757X","authenticated-orcid":false,"given":"Jos\u00e9 \u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, 28051 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Andreu-Lapiedra","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitario La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-4151","authenticated-orcid":false,"given":"Miguel","family":"Arguello-Tomas","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Leiva-Farr\u00e9","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"L\u00f3pez-Roda","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Callejo-Mell\u00e9n","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"\u00c1lvarez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-3758","authenticated-orcid":false,"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitario de la Princesa, 28004 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: Descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_3","unstructured":"(2023, August 02). SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia (CLL), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_4","first-page":"92","article-title":"Early intervention in asymptomatic chronic lymphocytic leukemia","volume":"19","author":"Muchtar","year":"2021","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdn460","article-title":"Chronic lymphocytic leukaemia: A short overview","volume":"19","author":"Montserrat","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","article-title":"Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia","volume":"116","author":"Shanafelt","year":"2010","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.31931","article-title":"Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11899-021-00637-1","article-title":"Frontline Treatment for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): Targeted Therapy vs. Chemoimmunotherapy","volume":"16","author":"Small","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_13","first-page":"185","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1080\/10428194.2023.2232489","article-title":"Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: Experience from one European center","volume":"64","author":"Albiol","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.V126.23.871.871","article-title":"Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies","volume":"126","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cam4.3855","article-title":"Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population","volume":"10","author":"Goyal","year":"2021","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/CLEP.S337495","article-title":"Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia","volume":"13","author":"Rotbain","year":"2021","journal-title":"Clin. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1016\/j.jval.2014.03.463","article-title":"Economic Cost of Adverse Events Per Course of Therapy with Commonly Used First-Line Regimens for the Treatment of Chronic Lymphocytic Leukemia","volume":"17","author":"Monberg","year":"2014","journal-title":"Value Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1002\/cam4.2559","article-title":"Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PPO.0000000000000407","article-title":"Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies","volume":"25","author":"Islam","year":"2019","journal-title":"Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/03007995.2021.1884540","article-title":"Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: Differences between patients treated with first-line ibrutinib or bendamustine + rituximab","volume":"37","author":"Irwin","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jha2.174","article-title":"Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK","volume":"2","author":"Hillmen","year":"2021","journal-title":"eJHaem"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","article-title":"Electronic health records to facilitate clinical research","volume":"106","author":"Cowie","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2200006","DOI":"10.1200\/CCI.22.00006","article-title":"Assessment of Electronic Health Record for Cancer Research and Patient Care Through a Scoping Review of Cancer Natural Language Processing","volume":"6","author":"Wang","year":"2022","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jamia\/ocab289","article-title":"Quantitating and assessing interoperability between electronic health records","volume":"29","author":"Bernstam","year":"2022","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/CCI.20.00020","article-title":"Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes","volume":"4","author":"Kehl","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jbi.2017.11.011","article-title":"Clinical information extraction applications: A literature review","volume":"77","author":"Wang","year":"2018","journal-title":"J. Biomed. Inform."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fu, S., Chen, D., He, H., Liu, S., Moon, S., Peterson, K.J., Shen, F., Wang, L., Wang, Y., and Wen, A. (2020). Clinical concept extraction: A methodology review. J. Biomed. Inform., 109.","DOI":"10.1016\/j.jbi.2020.103526"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40545-020-00276-6","article-title":"Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy","volume":"13","author":"Medrano","year":"2020","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40264-017-0558-6","article-title":"Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review","volume":"40","author":"Luo","year":"2017","journal-title":"Drug Saf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/picr.PICR_36_18","article-title":"Real world evidence (RWE)\u2014Are we (RWE) ready?","volume":"9","author":"Suvarna","year":"2018","journal-title":"Perspect. Clin. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2023-188292","article-title":"Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing","volume":"142","author":"Asti","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1002\/hem3.143","article-title":"Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms","volume":"8","author":"Duminuco","year":"2024","journal-title":"Hemasphere"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Loscertales, J., Abrisqueta-Costa, P., Gutierrez, A., Hernandez-Rivas, J.A., Andreu-Lapiedra, R., Mora, A., Leiva-Farre, C., Lopez-Roda, M.D., Callejo-Mellen, A., and Alvarez-Garcia, E. (2023). Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study. Cancers, 15.","DOI":"10.3390\/cancers15164047"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2400756","DOI":"10.1183\/13993003.03142-2020","article-title":"The impact of COVID-19 on patients with asthma","volume":"57","author":"Izquierdo","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e21801","DOI":"10.2196\/21801","article-title":"Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing","volume":"22","author":"Izquierdo","year":"2020","journal-title":"J. Med. Internet Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/jwh.2020.8721","article-title":"Evidence of Gender Differences in the Diagnosis and Management of Coronavirus Disease 2019 Patients: An Analysis of Electronic Health Records Using Natural Language Processing and Machine Learning","volume":"30","author":"Ancochea","year":"2021","journal-title":"J. Women\u2019s Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e20492","DOI":"10.2196\/20492","article-title":"Assessing the Performance of Clinical Natural Language Processing Systems: Development of an Evaluation Methodology","volume":"9","author":"Canales","year":"2021","journal-title":"JMIR Med. Inform."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/II PCYC-1102 Study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1080\/10428194.2017.1292353","article-title":"Efficacy and toxicity of compassionate ibrutinib use in relapsed\/refractory chronic lymphocytic leukemia in Poland: Analysis of the Polish Adult Leukemia Group (PALG)","volume":"58","author":"Hus","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.21873\/anticanres.14403","article-title":"Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study","volume":"40","author":"Pula","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1002\/ajh.24773","article-title":"Real-world results of ibrutinib in relapsed\/refractory CLL in France: Early results on a large series of 428 patients","volume":"92","author":"Ysebaert","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_53","first-page":"10","article-title":"Under-reporting of Adverse Events in the Biomedical Literature","volume":"1","author":"Kostoff","year":"2016","journal-title":"J. Data Inf. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: Modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V128.22.2406.2406","article-title":"Differences in Healthcare Utilization in CLL Patients Treated with BR Versus FCR","volume":"128","author":"Gabriel","year":"2016","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1197\/jamia.M1794","article-title":"Automated detection of adverse events using natural language processing of discharge summaries","volume":"12","author":"Melton","year":"2005","journal-title":"J. Am. Med. Inform. Assoc."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/4004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:42:31Z","timestamp":1760114551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/4004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":61,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16234004"],"URL":"https:\/\/doi.org\/10.3390\/cancers16234004","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}